The November 2010 issue of Nature reported that several large pharmaceutical companies, including AstraZeneca and GlaxoSmithKline, have chosen to pull out of the psychiatric pharmacology in the treatment of schizophrenia. The reason is obvious, according to Nature author, Abbott: The first generation of schizophrenia drugs (manufactured in the 1950s) and the second generation (manufactured in the 1990s) have not addressed the adverse side effects of antipsychotic drugs on patients…..
Reported by Amy Chaves
References: Abbott, A. (11 November, 2010). The drug deadlock. Nature, 468, 158-159.
Bagnall, A. M., Jones, L., Ginnelly, L., Lewis, R., Glanville, J., Gibody, S.,…Kleijnen, J. (2003). A systematic review of atypical antipsychotic drugs in schizophenia (Executive Summary). Health Technology Assessment, 7(13). Retrieved from http://www.hta.ac.uk/pdfexecs/summ7…
Dobbs, D. (11 November, 2010). The making of a troubled mind. Nature, 468, 154-156.
Disclaimer: Neither SARDAA nor SA, assume any legal liability, responsibility nor does inclusion of articles or comments constitute or imply its endorsement, recommendation, or favoring for the accuracy, completeness, or usefulness of any information, product or process disclosed in the blog.